HLA class II genotypes associated with chronic hepatitis C virus infection and response to α-interferon treatment in Poland

Liver

Volumn 20, Issue 3, 2000, Pages 234-239

  Wawrzynowicz Syczewska, Marta ^a   Underhill, James A ^b   Clare, Michael A ^b   Boron Kaczmarska, Anna ^a   McFarlane, Ian G ^b   Donaldson, Peter T ^b,c,d  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Chronic infection; DQA1*0301; Hepatitis C virus; HLA; Interferon ; Poland; Treatment

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; HEPATITIS B VACCINE; HLA ANTIGEN CLASS 2; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN;

ADULT; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE RESISTANCE; DRUG EFFICACY; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; POLAND; POLYMERASE CHAIN REACTION; VACCINATION;

ADULT; AGED; DNA; DNA PROBES, HLA; FEMALE; GENE FREQUENCY; GENES, MHC CLASS II; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HEPACIVIRUS; HEPATITIS C ANTIGENS; HEPATITIS C, CHRONIC; HISTOCOMPATIBILITY; HLA-DR ANTIGENS; HUMANS; IMMUNITY, NATURAL; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLAND; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

EID: 0034111771     PISSN: 01069543     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0676.2000.020003234.x     Document Type: Article

References (17)

1. VAN DER POEL C L, CUYPERS H T, REESINK H W. Hepatitis C virus six years on. Lancet 1994; 344: 1475-9.
2. ALTER M J, MARGOLIS H S, KRAWCZYNSKI K, et al. The natural history of community-acquired hepatitis C in the United States. The sentinel counties chronic non-A, non-B hepatitis study team. N Engl J Med 1992; 327: 1899-905.
3. TONG M J, EL FARRA N S, REIKES A R, CO R L. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-6.
4. DUSHEIKO G, SCHMILOVITZ WEISS H, BROWN D, et al. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 1994; 19: 13-8.
5. CRAMP M E, CARUCCI P, CHOKSHI S, et al. A multispecific T lymphocyte response to hepatitis C virus proteins occurs in patients with viral clearance and persists many years after exposure. Hepatology 1996; 24: 252A.
6. DONALDSON P T. The relationship between hepatitis C virus and HLA. Eur J Clin Invest 1999; 29: 280-3.
7. ALRIC L, FORT M, IZOPET J, et al. Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. Gastroenterology 1997; 113: 1675-81.
8. CRAMP M E, CARUCCI P, UNDERHILL J, NAOUMOV N V, WILLIAMS R, DONALDSON P T. Association between HLA class II genotype and spontaneous clearance of HCV infection. J Hepatol 1998; 29: 207-13.
9. ZAVAGLIA C, MARTINETTI M, SILINI E, et al. Association between HLA class II alleles and protection from or susceptibility to chronic hepatitis C. J Hepatol 1998; 28: 1-7.
10. MANGIA A, GENTILE R, CASCAVILLA I, et al. HLA DQB1*0301 and HCV: relationship with viral clearance. Hepatology 1998; 28: 359A [Abstract 787].
11. SVEJGAARD A, RYDER L P. HLA and disease associations: Detecting the strongest association. Tissue Antigens 1994; 43: 18-27.
12. LECHMANN M, SCHNEIDER E M, GIERS G, et al. Increased frequency of the HLA-DR15 (B1* 15011) allele in German patients with self-limited hepatitis C virus infection. Euro J Clin Invest 1999; 28: 337-43.
13. CZAJA A J, CARPENTER H A, SANTRACH P J, MOORE S B. Immunologic features and HLA associations in chronic viral hepatitis. Gastroenterology 1995; 108: 157-64.
14. CONGIA M, CLEMENTE M G, DESSI C, et al. HLA class II genes in chronic hepatitis C virus-infection and associated immunological disorders. Hepatology 1996; 24: 1338-41.
15. DONALDSON P T, MANNS M P. Immunogenetics of liver disease. In: BIRCHER J, BENHAMOU J-P, MCINTYRE N, RIZZETTO M, RHODES J eds. Oxford textbook of clinical hepatology 1999; 1: 173-88.
16. ALMARRI A, BATCHELOR J R. HLA and hepatitis B infection. Lancet 1994; 344: 1194-5.
17. MCDERMOTT A B, ZUCKERMAN J N, SABIN C A, MARSH S G E, MADRIGAL J A. Contribution of human leucocyte antigens to the antibody response to hepatitis B vaccination. Tissue Antigens 1997; 50: 8-14.